Cargando…
Active Stromal Cell–Derived Factor 1α and Endothelial Progenitor Cells are Equally Increased by Alogliptin in Good and Poor Diabetes Control
BACKGROUND: It is postulated that the ability of dipeptidyl peptidase-4 inhibitors (DPP-4-i) to increase circulating endothelial progenitor cells (EPCs) may be at least partly mediated by active stromal cell–derived factor 1α (SDF-1α) (a pivotal mediator of stem cell mobilization from the bone marro...
Autores principales: | Negro, Roberto, Greco, Eupremio Luigi, Greco, Giacomo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714079/ https://www.ncbi.nlm.nih.gov/pubmed/29225483 http://dx.doi.org/10.1177/1179551417743980 |
Ejemplares similares
-
Comparison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control
por: Churdchomjan, Worachat, et al.
Publicado: (2010) -
Increased Endothelial Progenitor Cell Levels are Associated with Good Outcome in Intracerebral Hemorrhage
por: Pías-Peleteiro, Juan, et al.
Publicado: (2016) -
Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
por: Kim, Hae Jin, et al.
Publicado: (2022) -
Enhancing Pancreatic Beta-Cell Regeneration In Vivo with Pioglitazone and Alogliptin
por: Yin, Hao, et al.
Publicado: (2013) -
Alogliptin benzoate for management of type 2 diabetes
por: Saisho, Yoshifumi
Publicado: (2015)